Find disease awareness content and relevant supporting materials

This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with...

Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway.

Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic...

Novartis has presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median...

This article summarizes the scientific review of the application leading to regulatory approval in the European Union.

Novartis announced that the European Commission has approved Farydak (panobinostat, previously known as LBH589) capsules, in combination with bortezomib and...

Novartis presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the...

Novartis has announced that the FDA Oncologic Drugs Advisory Committee (ODAC) did not recommend the investigational compound LBH 589 (panobinostat),...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for...

Novartis announced that the FDA has approved Farydak (panobinostat, previously known as LBH 589) capsules in combination with bortezomib and...